arav-8k_20201119.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2020

 

Aravive, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36361

26-4106690

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

River Oaks Tower

3730 Kirby Drive, Suite 1200

Houston, Texas 77098

(Address of principal executive offices)

 

(936) 355-1910

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ARAV

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 



Item 7.01.   Regulation FD Disclosure.

 

On November 19, 2020, Aravive, Inc. (the “Company”) issued a press release announcing that the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a Phase 3 trial design for AVB-500 in platinum resistant ovarian cancer (PROC). The global, randomized, double-blind, placebo-controlled adaptive trial is designed to evaluate efficacy and tolerability of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel.  A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In addition, the Company will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the investor presentation, which is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01, in the press release attached as Exhibit 99.1 and in the investor presentation attached as Exhibit 99.2 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, in the press release attached as Exhibit 99.1 and in the investor presentation attached as Exhibit 99.2 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The press release attached as Exhibit 99.1 and investor presentation attached as Exhibit 99.2 to this Current Report on Form 8-K include “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 8.01.   Other Events. 

On November 19, 2020, the Company issued a press release announcing that the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a Phase 3 trial design for AVB-500 in platinum resistant ovarian cancer (PROC). The global, randomized, double-blind, placebo-controlled adaptive trial is designed to evaluate efficacy and tolerability of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel. The Company noted that there was agreement from the FDA that the Company’s preclinical and clinical pharmacology programs are now complete, and that this trial, if successful, could support the submission of a biologics license application to the FDA. The Company plans to initiate the trial in the first quarter of 2021, with an interim analysis expected a year later, Q12022.

The pivotal, adaptive Phase 3 trial is expected to enroll approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy. This global trial is expected to be conducted at approximately 100 sites in the U.S. and Europe. The primary endpoint for the trial is progression free survival, and secondary endpoints include overall survival, objective response rate, duration of response, quality of life, clinical benefit rate, and pharmacokinetic and pharmacodynamic profile. Prospectively defined interim analyses will investigate treatment differences in patients who have previously received bevacizumab versus those who have not and will explore the biomarkers identified in the Phase 1b trial in an effort to test the hypotheses generated from the Phase 1b data. Based on the interim analyses, the trial can be adapted to include only those patients who have not previously been treated with bevacizumab and/or whose baseline serum biomarker results meet the identified threshold.

 

Item 9.01.   Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished to this Current Report on Form 8-K:

 

 

 

 

 

 

Exhibit

Number

 

Description

99.1

 

Press Release dated November 19, 2020

99.2

  

Investor Presentation of Aravive, Inc dated November 2020

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: November 19, 2020

ARAVIVE, INC.

(Registrant)

 

 

 

 

By:

 

/s/ Gail McIntyre           

 

Name:

 

Gail McIntyre

 

Title:

 

Chief Executive Officer

 

 

 

 

arav-ex991_149.htm

Exhibit 99.1

 

Aravive Announces Phase 3 Trial Design for AVB-500 in
Platinum Resistant Ovarian Cancer

 

Pivotal Trial Expected to be Initiated During 1Q21

 

Houston, TX, November 19, 2020 – Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a Phase 3 trial design for AVB-500 in platinum resistant ovarian cancer (PROC). The global, randomized, double-blind, placebo-controlled adaptive trial is designed to evaluate efficacy and tolerability of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel.  

 

“We look forward to advancing AVB-500 into a pivotal Phase 3 trial in platinum resistant ovarian cancer, following the promising results from our Phase 1b trial and productive conversations with the FDA,” said Gail McIntyre, Ph.D., Chief Executive Officer of Aravive. “With agreement from the FDA that our preclinical and clinical pharmacology programs are now complete, we anticipate that this trial, if successful, could support the submission of a biologics license application to the FDA. We plan to initiate the trial in the first quarter of 2021, with an interim analysis expected a year later.”

 

The pivotal, adaptive Phase 3 trial is expected to enroll approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy. This global trial is planned to be conducted at approximately 100 sites in the U.S. and Europe. The primary endpoint for the trial is progression free survival, and secondary endpoints include overall survival, objective response rate, duration of response, quality of life, clinical benefit rate, and pharmacokinetic and pharmacodynamic profile. Prospectively defined interim analyses will investigate treatment differences in patients who have previously received bevacizumab versus those who have not and will explore the biomarkers identified in the Phase 1b trial in an effort to test the hypotheses generated from the Phase 1b data. Based on the interim analyses, the trial can be adapted to include only those patients who have not previously been treated with bevacizumab and/or whose baseline serum biomarker results meet the identified threshold.

 

About AVB-500

AVB-500 is a therapeutic recombinant fusion protein that has been shown to neutralize GAS6 activity by binding to GAS6 with very high affinity in preclinical models. In doing so, AVB-500 selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian cancer. In preclinical studies, GAS6-AXL inhibition has shown anti-tumor activity in combination with a variety of anticancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. Increased expression of AXL and GAS6 in tumors has been correlated with poor prognosis and decreased survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies. AVB-500 is currently being evaluated in clinical trials and has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. Analysis of all safety data to date showed that AVB-500 has been generally well-tolerated with no dose-limiting toxicities or unexpected safety signals.  

 

 

 


 

 

About Aravive

Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive recently successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and selected 15 mg/kg as the dose for the Phase 3 trial. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company also intends to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma later this year. For more information, please visit www.aravive.com.

 

Forward-Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended), express or implied, such statements regarding advancing AVB-500 into a pivotal Phase 3 trial during first quarter 2021, the trial supporting the submission of a biologics license application to the FDA, conducting an interim analysis a year later, enrollment of approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy, the trial being conducted at approximately 100 sites in the U.S. and Europe. Forward-looking statements are based on current beliefs and assumptions, are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement as a result of various factors, including, but not limited to, risks and uncertainties related to: our ability to initiate a pivotal trial during first quarter 2021, the trial supporting the submission of a biologics license application to the FDA, our ability to conduct an interim analysis a year later, as planned, our ability to enroll approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy as planned, our ability to conduct the trial at approximately 100 sites in the U.S. and Europe as planned, our ability to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma as planned later this year, the impact of COVID-19 on the Company's clinical strategy, clinical trials, supply chain and fundraising, the Company's ability to expand development into additional oncology indications, the Company's dependence upon AVB-500, AVB-500's ability to have favorable results in clinical trials and ISTs, the clinical trials of AVB-500 having results that are as favorable as those of preclinical and clinical trials, the ability to receive regulatory approval, potential delays in the Company's clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients especially in light of the COVID-19 pandemic; the risk that AVB-500 may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that the Company may encounter difficulties in manufacturing AVB-500; if AVB-500 is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing the Company's intellectual property rights; the Company's reliance on its licensor of intellectual property and financing needs. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, recent Current Reports on Form 8-K and subsequent filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 


 

# # #

 

Contacts:
Media:

Sheryl Seapy, W2O

sseapy@w2ogroup.com

(213) 262-9390

 

Investors:
Luke Heagle, W2O  

lheagle@w2ogroup.com

(910) 726-1372

 

 

 

arav-ex992_28.pptx.htm

Slide 1

© 2020 Aravive, Inc. Corporate Presentation November 2020 Halting Disease Progression in its Tracks ARAV (NASDAQ) Exhibit 99.2

Slide 2

© 2020 Aravive, Inc. Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and they often include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements included in this presentation include statements regarding Aravive’s planned clinical activities, including the design, initiation, patient enrollment and availability of data from clinical studies, potential pipeline, future indications and cash position and the anticipated safety, activity and manufacturability of Aravive’s product candidates. Forward-looking statements are based on Aravive’s current beliefs and assumptions, are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: Aravive’s ability to initiate a pivotal trial during first quarter 2021, the trial supporting the submission of a biologics license application to the FDA, Aravive’s ability to conduct an interim analysis late next year, as planned, Aravive’s ability to enroll approximately 300-400 patients with high-grade serous ovarian cancer who have received one to four prior lines of therapy as planned, Aravive’s ability to conduct the trial at approximately 100 sites in the U.S. and Europe as planned, Aravive’s ability to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma as planned later this year, the impact of COVID-19 on Aravive's clinical strategy, clinical trials, supply chain and fundraising, Aravive's ability to expand development into additional oncology indications, Aravive's dependence upon AVB-500, AVB-500's ability to have favorable results in clinical trials and ISTs, the clinical trials of AVB-500 having results that are as favorable as those of preclinical and clinical trials, the ability to receive regulatory approval, potential delays in Aravive's clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients especially in light of the COVID-19 pandemic; the risk that AVB-500 may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that Aravive may encounter difficulties in manufacturing AVB-500; if AVB-500 is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing Aravive's intellectual property rights; Aravive's reliance on its licensor of intellectual property and financing needs. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Aravive’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. Except as required by law, Aravive undertakes no obligation to revise or update any forward-looking statement or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Slide 3

© 2020 Aravive, Inc. Aravive Senior Management and Board of Directors Board of Directors Senior Management Gail McIntyre, Ph.D., DABT CEO Reshma Rangwala, M.D., Ph.D. CMO Fred Eshelman, Pharm D. Chairman of the Board Amato Giaccia, Ph.D. Director Michael Rogers Director Gail McIntyre, Ph.D., DABT Director Raymond Tabibiazar, M.D. Director Eric Zhang Director Vinay Shah CFO Randy Anderson, Ph.D. SVP of Data Sciences Patrick Simms VP of Clin Ops Elisabeth Gardiner, Ph.D. VP of Translational Medicine

Slide 4

© 2020 Aravive, Inc. | CONFIDENTIAL Aravive Top Shareholders Insiders, Institutional Shareholders Make Up >70% of Our Outstanding Shares % Ownership** 24.3% % of Shares Held by Insiders 46.3% % of Shares Held by Institutional Investors* * As per SEC filings – 13D, 13F, 13G, Forms 3 and Form 4, Proxy ** As of 9/30/2020 Top 10 Shareholders* % Ownership** Invus Public Equities Advisors 8.2% Tabibiazar, Raymond (Board member) 6.2% New Leaf Biopharma Opportunities 5.9% Giaccia, Amato (Board member) 5.9% Eshelman Ventures (Board member) 5.8% Elite Vantage Global Limited (Board Member) 5.3% BC Axis Limited 5.3% BlackRock 4.3% The Vanguard Group 3.5% Renaissance Technologies 3.2%

Slide 5

© 2020 Aravive, Inc. Serious Cancers High Unmet Medical Need Clinical Programs Focused on Tumors That Express GAS6/AXL Company Focus

Slide 6

GAS6 and AXL are overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival GAS6 is growth factor that regulates several biologic processes in cells through interaction with its receptors, including AXL, Tyro3, and Mer GAS6 is the sole activating ligand of AXL Associated with acquired resistance to chemotherapy, platinum-containing therapy, and targeted agents Inhibition of GAS6 & AXL has no toxicity to normal tissue © 2020 Aravive, Inc. Combo DDRs, PARPi VEGFi & TKIs Resistance to: Chemotherapy, Radiotherapy, Targeted Therapy Combo with IOs Immune Suppression Combo with ChemoTx Resistance to apoptosis/autophagy Invasive Cancers like PROC, RCC, Bladder EMT and Metastasis Leukemia Proliferation Uniquely Focused on GAS6/AXL Signaling Pathway

Slide 7

© 2020 Aravive, Inc. GAS6 and/or AXL Expression Is Associated with Poor Survival in Many Cancers Tumor Type AXL Tumor Expression1 Ovarian >70% Hao et al. 2017. AXL is highly expressed in ovary-derived tumors and is a prognostic gene in ovarian cancer. Rankin et al 2010. 73% of all ovarian tumor samples including both type I and type II tumors were positive for membranous AXL staining in the epithelium, demonstrating that AXL expression is significantly higher (P < 0.0001) in ovarian carcinomas than normal ovarian epithelium. Pancreatic 70% Song et al. Cancer 2011. February 15;117(4):734–43. AXL is overexpressed in 70% stage II PDAC tumor samples. Bladder >45% Wang et al Transl Cancer Res 2019;8(3):976-984. High AXL expression was strongly correlated with low OS (P<0.001). Uterine >75% Divine et al. Oncotarget. 2016 Nov 22; 7(47): 77291–77305: High immunohistochemical expression of AXL was found in 76% of advanced- stage, and 77% of high-grade specimens and correlated with worse survival in uterine serous cancer patients. Kidney >70% Dalgin et al. 2007: AXL expression is 3 fold higher in tumor tissue than normal tissue. Gustafsson et al. 2009: AXL and GAS6 expression are implicated in RCC tumor advancement and severity and negatively correlated to patient survival. Breast >75% Bottai et al. Breast Cancer. 2016. AXL expression correlates with the infiltration of CD163-positive cells in tumor stroma and is associated with survival in triple negative breast cancer. Lung 18-48% Seike et al. Oncology Rep. 2017. 37: 3261-3269. The 5-yr survival rate for AXL+ or GAS6+ was significantly lower than those for AXL- or GAS6- patients (51% vs. 75%; P=0.028; 53% vs. 72%; P=0.040) Linger et al. 2012. Expert Opin Ther Targets. 2010 October ; 14(10): 1073–1090 AXL protein expression was observed in 28 of 58 (48.3%) patient samples of lung adenocarcinoma 1 The Cancer Genome Atlas (TCGA): (https://cancergenome.nih.gov); Axelrod and Pienta (AXL Review) : Oncotarget. 2014 Oct; 5(19): 8818–8852; Miao et al (AXL Review): 2017. Drug Target Review Article 22309. “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis." Wu G, et al. Molecular insights of Gas6/TAM in cancer development and therapy; Cell Death and Disease (2017) 8, e2700.

Slide 8

© 2020 Aravive, Inc. COMPANY DRUG (STAGE) TARGET SELECTIVE FOR AXL ARAVIVE AVB-500 (Ph Ib/II) GAS6 YES Astellas gilteritinib (Market; AML) AXL (Multi-kinase) NO Exelixis cabozantinib (Market; RCC & HCC) AXL (Multi-kinase) NO Mirati (BeiGene) sitravatinib (Ph III) AXL (Multi-kinase) NO Lilly merestinib (Ph II) AXL (Multi-kinase) NO BerGenBio bemcentinib (Ph II) AXL (Multi-kinase) NO Tolero (Sumitomo) TP-0903 (Ph I/II) AXL (Multi-kinase) NO Other approaches to targeting GAS6/AXL signaling have drawbacks which limit their ability to effectively target this pathway TKIs lack selectivity, leading to off-target toxicity, and tumor cells often acquire resistance Monoclonal antibodies do not have a high enough affinity to compete with and disrupt the high-affinity GAS6/AXL interaction Engineered Decoy Receptor is Preferred Approach for Potent and Selective Inhibition of GAS6/AXL Signaling

Slide 9

© 2020 Aravive, Inc. AVB-500: First- and Potential Best-In-Class Opportunity in Oncology Ultra-high affinity decoy protein that targets the GAS6/AXL signaling pathway Neutralizes GAS6 , starving tumors of signal that promotes growth, invasion, and metastasis Well-tolerated , with no unexpected dose-limiting safety or tolerability issues Granted Fast Track Designation from FDA in PROC I dea l P r o f ile f o r C o m b i na t i o n w i t h c he m otherapy , c he c k p o i n t i nh i b i t o rs an d P A R P i nh i b i t o rs in b r oa d r ang e o f i nd i c a t i o n s

Slide 10

© 2020 Aravive, Inc. Platinum Resistant Ovarian Cancer (PROC) Lead Program: AVB-500 in Platinum Resistant Ovarian Cancer (PROC) 5th LEADING CAUSE OF DEATH among women in the U.S. (Ovarian Cancer) ~70% OF PATIENTS are diagnosed with advanced disease 50% 5-YEAR relative survival (9-12 months PROC) LESS THAN

Slide 11

AVB-500 follows target-mediated drug disposition (TMDD) kinetics, consistent with other Fc proteins and antibodies. Used a model-informed drug development approach (MIDD) to identify RP2D; PK/PD translated from pre-clinical to clinical. Exposure response (E-R) analysis demonstrated that subjects with cycle 1 trough concentrations (C1D15) >13.8mg/L had longer mPFS relative to peers with lower cycle 1 trough concentrations. PK model simulations predicted that 84.2% of subjects treated with the RP2D of 15mg/kg IV Q2W would have a cycle 1 trough above the 13.8mg/L threshold established by the E-R analysis. © 2020 Aravive, Inc. AVB-500 in PROC: Phase 1a and 1b PK/PD Summary Data AVB-500 + PAC, > MEC – mPFS: 7.5 AVB-500 + PAC, < MEC – mPFS: 2.8 MEC = minimal efficacious concentration, 13.8 mg/L Probability

Slide 12

© 2020 Aravive, Inc. AVB-500 (AVB): q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1 of 28-day cycle; Paclitaxel (PAC) 80 mg/m2 day 1, day 8, day 15 of 28-day cycle Maintenance dosing on AVB-500 monotherapy AVB 500 10 mg/kg + PLD (N=21) AVB 500 15 mg/kg + PLD (N=2) Select RP2D AVB 500 10 mg/kg + PAC (N=16) AVB 500 15 mg/kg + PAC (N=3) PLATINUM-RESISTANT OVARIAN CANCER AVB 500 20 mg/kg + PLD (N=3) AVB 500 20 mg/kg + PAC (N=4) Key Eligibility Criteria 1-3 prior lines of therapy Measurable disease Platinum free interval ≤ 6mo after most recent platinum-containing regimen Adults with adenocarcinoma NOS, high grade endometrioid adenocarcinoma, mixed epithelial (≥ 80% high grade serous), high grade serous, or undifferentiated carcinoma ECOG performance status 0-1 Primary endpoint: safety and tolerability; not powered for efficacy iDMC= Independent Data Monitoring Committee NOS= Not Otherwise Specified ECOG= Eastern Cooperative Oncology Group iDMC Review iDMC Review Lead Program: AVB-500 in PROC – Phase 1b Trial

Slide 13

© 2020 Aravive, Inc. Efficacy Data for 10mg/kg and 15mg/kg Patients: >MEC PAC (N=10) PLD (N=14) mPFS (months) 7.5 3.7 ORR 5 (50%) [2 CRs^ (20%)] 2 (14%) mDoR (months) 7.4 5.3 mOS (months)* 19.0 12.7 Phase 1b Trial: Efficacy Data for Patients with Greater Than MEC (10mg/kg and 15mg/kg Patients) MEC = minimal efficacious concentration (13.8mg/L) mDoR = median duration of response; mOS = median overall survival; mPFS = median progression free survival ^1 patient at 10mg/kg and 1 patient at 15mg/kg had CR; 1 patient at 15mg/kg with CR continues to show CR at C13D1 while on AVB-500 alone, 6 months after discontinuing paclitaxel *Study ongoing so data can change

Slide 14

© 2020 Aravive, Inc. AVB-500 + PAC and Prior Bev Use for 10mg/kg and 15mg/kg Patients Bev Naïve (n=9) Previous Bev (n=10) mPFS (months) 7.7 2.8 ORR 6 (67%) [2 CRs^ (22%)] 1 (10%) mDoR (months) 7.2 3.7 mOS (months)* 19.3 9.2 Phase 1b Trial: Efficacy Data AVB-500 + PAC and Prior Bevacizumab Use 10mg/kg and 15mg/kg Patients Note: AVB-500 + PAC and >MEC in bev naïve patients (n=7): mPFS 9.1 months and ORR of 71% Third-Party Published Data as Benchmark (AURELIA Study1) Subgroup analysis of the control arms in the AURELIA (NCT00976911) bevacizumab study has shown: Benefit observed with AVB-500 + PAC was among patients with worse prognostic factors than reported from the AURELIA study. Historical 3rd-party data are for illustrative purposes only; Aravive P1b trial was not powered to demonstrate efficacy. ORR of 30.2% with PAC alone (N=55) mPFS of 3.9 months with PAC alone (N=55) 1 Journal of Clinical Oncology, Vol 33, No 32 (November 10), 2015: pp 3836-383 ^ 1 patient at 10mg/kg and 1 patient at 15mg/kg had CR ; 1 patient with CR continues to show CR at C13D1 while on AVB-500 alone, 6 months after discontinuing paclitaxel *Study ongoing so data can change

Slide 15

© 2020 Aravive, Inc. Potential Biomarker: Serum Levels of sAXL/GAS6 Ratio Correlated with Response to AVB-500 + Chemo sAXL/GAS6 >0.773 AVB-500 + PAC (10 and 15 mg/kg patients) Yes (>0.773) NO N 11 7 CR 2 (18%) 0 PR 4 (36%) 0 ORR 6 (55%) 0 SD 3 (27%) 4 (57%) CBR 9 (82%) 4 (57%) PD 2 (18%) 3 (43%) 55% (6/11) ORR in PAC Cohort 1 patient from 10mg/kg and 1 patient from 15mg/kg group had CR CBR = clinical benefit rate (ORR + SD); mDoR = median duration of response; mOS = median overall survival; mPFS = median progression free survival

Slide 16

© 2020 Aravive, Inc. mPFS for 10 and 15 mg/kg PAC Groups by Biomarker and Prior Bevacizumab Use AVB-500 + PAC sAXL/GAS6 >0.773 Yes No Yes No BEV NAÏVE PREV BEV N 6 2 5 5 mPFS (months) 8.4 2.7 2.8 2.9 Probability

Slide 17

© 2020 Aravive, Inc. mOS for 10 and 15 mg/kg PAC Groups by Biomarker and Prior Bevacizumab Use AVB-500 + PAC sAXL/GAS6 >0.773 Yes No Yes No BEV NAIVE PREV BEV N 6 2 2 5 5 mOS* (months) Not eval (Lower 95% CI = 19.3) 8.5 8.5 9.2 9.2 *Study ongoing so data can change

Slide 18

CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS WITH <3MO PFI PER KOBAYASHI-KATO ET AL, 2019 (N=21) CLINICAL RESPONSE OF AVB-500+CHEMO IN PATIENTS WITH <3MO PFI ORR= objective response rate; SD=stable disease; CBR=clinical benefit rate; PD=progressive disease; PFI=platinum-free interval 12 patients in the high exposure AVB-500 +chemo group; Two responders in chemo + AVB-500 high exposure group had CR. Historical data from Cancer Chemotherapy and Pharmacology (2019) 84:33-39 37; included PLD; GEM; CPT-11 (irinotecan); topotecan; and paclitaxel; no CRs in historical data (1 PR in historical data) Updated Analysis for High-Exposure Patients (>MEC) AVB-500 + Chemo Showed Improved Clinical Benefit in Patient Subsets that Generally Respond Poorly to Chemo (PFI < 3 months) *All doses and both chemo cohorts

Slide 19

CLINICAL RESPONSE OF AVB-500+CHEMO IN 3L AND 4L CLINICAL RESPONSE OF CHEMOTHERAPY IN 3L AND 4L PER BRUCHIM ET AL, 2013 (N=99) 20 patients in the high exposure AVB-500+chemo group; Two CRs in High Exposure Category Updated Analysis for High-Exposure Patients (>MEC) ORR= objective response rate; SD=stable disease; CBR=clinical benefit rate; PD=progressive disease; Historical data from European Journal of Obstetrics & Gynecology and Reproductive Biology 166 (2013) 94–98; 3L included (in order of use) taxol, carboplatin, topotecan, etoposide, gemzar, doxil, tamoxifen, adriamycin, carbo+taxol, and "other“; 4L was predominantly taxol. AVB-500 + Chemo Showed Improved Clinical Benefit in Patient Subsets that Generally Respond Poorly to Chemo (Later Lines of Therapy) *All doses and both chemo cohorts

Slide 20

Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE severity and frequency are consistent with expectations of the concomitant treatment (PAC or PLD) and the disease under study (ovarian cancer).” AVB-500 well-tolerated: fatigue and infusion reactions appeared to be related to treatment No serious events that required expedited reporting per Sponsor No drug related SAEs reported to date No dose-limiting toxicities 53 PROC Patients Dosed: 10 mg/kg (40); 15 mg/kg (6); and 20 mg/kg (7) © 2020 Aravive, Inc. Strong Safety Profile of AVB-500

Slide 21

© 2020 Aravive, Inc. Consistent with hypothesis that trough levels are associated with clinical activity, all 5 evaluable patients in 15 mg/kg cohort achieved MEC by their first CT scan, following four doses of AVB-500. Updated modeling using all patient data suggest that at 15mg/kg, pharmacokinetics of AVB-500 starts to plateau and 20mg/kg is not predicted to improve mPFS. 1 Complete Response 2 Stable Disease 2 Partial Responses 5/5 patients demonstrated clinical benefit: Post-hoc analysis of tumor expression showed that four 20mg/kg patients whose best response was PD did not express GAS6 (3) and/or had low amounts of AXL (2) on IHC of their tumors. Although enrolled per protocol, these 20mg/kg patients are not representative of the eventual AVB-500 target population, as they are mostly rare subtypes of PROC and will not be eligible for the planned Phase 3 trial. Selected 15mg/kg Dose for AVB-500 Phase 3 Registrational Trial in PROC

Slide 22

Conclusions and Recommendations for Phase 3 Registrational Trial in PROC Clinical activity of AVB-500 plus chemo was more pronounced in bev naïve patients P3 trial will stratify by previous bev use and interim analyses in a robust setting will allow us to interrogate magnitude of AVB-500 benefit in the prior bev subset Serum levels of sAXL/GAS6 ratio correlated with response to AVB-500 + chemo P3 trial will explore potential biomarkers, including serum sAXL/GAS ratio Clinical activity of AVB-500 plus chemo was more pronounced in bev naïve patients with sAXL/GAS6 ratio >0.773 Interim analyses will explore potential biomarkers and prior bev treatment with the ability to adapt and enrich patient population Patients with C1D15 trough levels >13.8mg/L (MEC) had longer mPFS vs patients <13.8mg/L P1b PK model simulations predicted that 84.2% of subjects treated with the RP2D of 15mg/kg would have a cycle 1 trough above the 13.8mg/L threshold established by the E-R analysis; all patients would be above 13.8mg/L by first CT scan Patients receiving AVB-500 + PAC responded better overall than AVB-500 + PLD patients P3 trial will move forward with AVB-500 + PAC and PAC + placebo

Slide 23

Potential Registrational Study Primary objective to assess anti-tumor activity of AVB-500 in combination with PAC as measured by PFS Secondary endpoints: OS, ORR based on RECIST 1.1, DOR, QoL, CBR, PK/PD Patients with high-grade serous ovarian cancer only; stratified by prior bevacizumab use, ECOG, prior lines, and platinum-free interval Interim analyses exploring potential biomarkers and prior bevacizumab treatment with ability to adapt and enrich patient population Exploratory biomarkers: serum GAS6, AVB-500 drug levels, serum sAXL/GAS6 ratio Q12021 initiation Randomized, Double-Blind, Placebo-Controlled Trial to Compare Efficacy and Tolerability of AVB-500 + PAC versus PAC AVB-500 + PAC Placebo + PAC Platinum-Resistant Ovarian Cancer 300-400 patients 1-4 prior lines ECOG 0-1 AVB-500 Phase 3 Adaptive Registrational Trial Design in PROC © 2020 Aravive, Inc. FDA feedback received Q420: study could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time

Slide 24

Potential Registrational Study © 2020 Aravive, Inc. AVB-500 Competitive Advantage in PROC Potentially More Favorable Benefit/Risk Profile and Well-Positioned for 1L Favorable Safety Profile to Date NO DLTs like chemotherapies and ADCs NO dose reductions or discontinuations to manage toxicities Administered with therapies that physicians can manage No toxicities that have been seen with ADCs: neutropenia, ocular toxicities, peripheral neuropathy, and/or liver enzyme elevation Infusion reactions and fatigue appeared to be related to treatment ORR of 37% in 10 and 15mg/kg PAC patients, regardless of trough levels Compelling anti-tumor activity in 10 and 15mg/kg PAC patients whose trough levels exceeded MEC

Slide 25

Potential Registrational Study © 2020 Aravive, Inc. Other Studies in PROC AVB-500 + PAC >MEC N=10 XMT-1536 N=47 Mirvetuximab soravtansine N=248 ITT = 366 Tumor Type Ovarian (80%) 1o peritoneal (20%) Ovarian (72%) Fallopian Tube (15%) 1o peritoneal (13%) Ovarian (83%) Fallopian Tube (6%) 1o peritoneal (11%) ECOG 0-1 0-1 0-1 Prior Lines 1-3 (5 w/ 2 & 5 w/ 3) 1-3, 4+ (2 pts w/ 5) 1-3 Prev. Tx Bev (30%) PARPi (30%) Bev (70%) PARPi (53%) Bev (49%) PARPi (11%) PFI 0-3 mths: 50% 3-6 mths: 50% >6 mths: 0 0-3 mths: 30% 3-6 mths: 57% >6 mths: 11% Unknown: 2% 0-3 mths: 30% 3-6 mth: 57% ≥ 6 mths: 4% Sources: 2020 ESMO Virtual Conference: Updated Interim Expansion Data From XMT-1536 Phase 1 Study (September 17, 2020) ESMO 2019 FORWARD I Results

Slide 26

Potential Registrational Study © 2020 Aravive, Inc. AVB-500 Competitive Advantage in PROC Potentially More Favorable Benefit/Risk Profile AVB-500 + PAC 10/15mg/kg >MEC XMT-1536, higher NaPi2b/ALL Mirvetuximab soravtansine, ITT FRα-positive N 10 20/29 366 (2:1 R) ORR 5 (50%) [3 PRs (30%); 2 CRs (20%)] 7 (33%) [5 PRs (25%); 2 CRs (10%)] / 10 (34%) [8 PRs (28%); 2 CRs (7%)] 22% [not broken out] SD 3 (30%) 10 (50% ) /13 (45%) Not reported PD 2 (20%) 3 (15%) / 6 (21%) Not reported mPFS (months) 7.5 Not reported 4.1 mDoR (months) 7.4 Not reported Not reported mOS (months)* 19.0 Not reported 15.6 Discontinuation due to AEs 0 4% (may be across NSCLC, PLT-S & PLT-R) 5% Dose reductions 0 Not reported 20% For illustrative purposes only, Data not generated from comparative study. Variation in study design including patient eligibility, response criteria, and assessment can affect outcomes and limit comparisons across studies. Sources: 2020 ESMO Virtual Conference: Updated Interim Expansion Data From XMT-1536 Phase 1 Study (September 17, 2020) ESMO 2019 FORWARD I Results *Study ongoing so data can change; Ns small

Slide 27

© 2020 Aravive, Inc. Current Oncology Pipeline: ccRCC Clear Cell Renal Cell Carcinoma (ccRCC) 15% 70k RESISTANCE To CHEMO OVER LESS THAN 5-YEAR relative survival for metastatic renal cancer NEW CASES expected in the U.S. in 2020 Is Common

Slide 28

© 2020 Aravive, Inc. Current Oncology Pipeline: Clear Cell Renal Carcinoma (ccRCC) Strong biological rationale for clear cell Renal Cell Carcinoma (ccRCC)1 VHL tumor suppressor gene mutated in at least 80%, causes increase in AXL AXL/GAS6 levels predict prognosis and survival in human1 Strong in vivo activity in preclinical models1,2 Single agent in metastatic disease Combo with TKI Rankin et al, PNAS | September 16, 2014 | vol. 111 | no. 37 | 13375 Xiao et al, Cancer Research October 4, 2019; AXL Expression (normalized) Normal Kidney (Class 1, n=9) Tissue and ccRCC Tumors (Class 2, n=9)

Slide 29

© 2020 Aravive, Inc. Single Agent Efficacy in Highly Metastatic Renal Model (SN12L1) 5mg/kg AXL decoy administered twice/wk 10 mg/kg administered QOD AVB-S6 Rankin et al, PNAS, September 16, 2014, vol. 111, no. 37, 13373–13378 Note: S6-1 and AVB-S6 are related AXL decoy proteins; both in S6 family

Slide 30

© 2020 Aravive, Inc. AVB-500 and TKI Combination Significantly Reduced Growth Rate in TKI-Resistant Renal PDX Xiao et al, Cancer Res 2019;79:5758–68 AVB-S6 is AVB-500 Control Pazopanib AVB-S6 AVB-S6+Pazopanib Control Pazopanib AVB-S6 AVB-S6+Pazopanib

Slide 31

Phase 1b Trial of AVB-500 in Combination with Cabozantinib Up to 18 patients; ability to increase/decrease dose based on tolerability, PK/PD On track to initiate end 2020 Phase 2 Controlled, Randomized Trial Primary endpoint: mPFS Secondary endpoints: ORR, mDoR, CBR, and mOS Histologically confirmed stage IV ccRCC progressed after 1L1 Cabozantinib is used most frequently in 2L AVB-500 + Cabo (N=9–18) AVB Dose Levels: DL -1: 10 mg/kg 2QW DL 1: 15 mg/kg Q2W DL 2: 20 mg/kg Q2W DL 3: 25 mg/kg Q2W AVB-500 + Cabo (N=30) Cabo Alone (N=15) 2 : 1 Safety to determine AVB-500 RP2D Phase 1b Phase 2 1American Joint Commission on Cancer, seventh edition, classification © 2020 Aravive, Inc. Current Oncology Pipeline: AVB-500 Phase 1b / Phase 2 Trial Design in ccRCC Cabo dosing will remain as indicated on the package insert

Slide 32

© 2020 Aravive, Inc. ccRCC Competitive Treatment Landscape NCCN guidelines preferred regimens include cabozantinib, nivolumab (both category 1). However, there are various other treatment options available in the relapsed ccRCC treatment landscape including Inlyta (category 1), Afinitor, or the combination of Lenvima plus Afinitor (category 1). Summarized results* for various 2nd line pivotal trials in the ccRCC treatment landscape are below: Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. RECORD-1 Everolimus vs placebo (2:1) N=410 AXIS Axitinib vs sorafenib (1:1) N=723 CheckMate 025 Nivolumab vs everolimus (1:1) N=821 METEOR Cabozantinib vs everolimus (1:1) N=658 Study 205 Lenvatinib + everolimus vs Lenvatinib vs everolimus (1:1:1) N=153 mPFS (months) 4.0 vs 1.9 6.7 vs 4.7 4.6** vs 4.4** 7.4 vs 3.9 12.8 vs 9.0 vs 5.6 Primary mOS (months) Not reached vs 8.8 Not reported 25.0 vs 19.6 Not reported 25.5 vs 18.4 vs 17.5 Follow-up mOS (months) 14.8 vs 14.4 20.1 vs 19.2 Not reported 21.4 vs 16.5 25.5 vs 19.1 vs 15.4 ORR (%) 1 vs 0 19 vs 9 25** vs 5** 17 vs 3 35 (2 CR) vs 39 (2 CR) vs 0 Dose reductions 5 vs <1 31 vs 52 NA vs 26 60 vs 25 71*** vs 62 vs 26 Dose delays 34 vs 15 77 vs 80 51 vs 66 Not reported Not reported Discontinuation due to AEs 10 vs 4 4 vs 8 8 vs 13 9 vs 10 24 vs 25 vs 12 *Variation in study design including patient eligibility, response criteria, and assessment can affect outcomes and limit comparisons across studies. **Investigator (all data without ** are from independent radiologic review (IRR). ***All lenvatinib dose reductions (1 patient also had everolimus dose reduction) Tannir NM, Pal SK, Atkins MB. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist. 2018;23(5):540-555. doi:10.1634/theoncologist.2017-0534

Slide 33

© 2020 Aravive, Inc. | CONFIDENTIAL Market Opportunity – AVB-500: PROC and ccRCC Indications Addressable Market PROC1 ccRCC2 US EU5 US EU5 Estimated Patient Population ~12K ~11K ~9K ~9K 2L-4L platinum-resistant ovarian cancer (PROC), high grade serous patients 2L advanced/metastatic clear cell renal cell carcinoma (ccRCC) patients Numbers represent company estimates of US and EU5 (France, Germany, Italy, Spain, UK) patients with conditions covered by the Company’s targeted indications Source: Decision Resource Group, diagnosed drug-treatable patients forecast. Aravive estimates. Total Market Ovarian Renal 2018 $2.3B $3.1B 2028 $9.6B $7.3B Annual Growth Rate 15.6% 9.1% Source: Decision Resource Group. Covers US, EU5 (France, Germany, Italy, Spain, UK) and Japan

Slide 34

© 2020 Aravive, Inc. AVB-500 Development Strategy: Basket Trial Concepts To Efficiently Expand Pipeline Efficiently expands the number of unique tumor types in which AVB-500 in combination is being evaluated and expands the AVB-500 treated market Combines with agents that are currently embedded as SOC in multiple tumor types and expands unique combination partners/mechanisms of actions that may demonstrate safety and efficacy Positions AVB-500 in earlier lines of therapy Cost effective Provides safety and preliminary evidence of activity that can drive registrational pathways Combination basket trials COMMON in oncology development including Keynote 021, Checkmate 12, Innova205, TOPACIO, EV-103, Mirvetuximab ph 1/2 combo, sitravatinib + PD-1 ph 1/2 combos

Slide 35

Potential Registrational Study © 2020 Aravive, Inc. Potential Trials: AVB-500 + PARP and AVB-500 + PD1 Basket Trials Phase 1b/2 Basket Trial of AVB-500 + PARP Inhibitor Potential indications: HER- breast cancer, pancreas, uterine, ovarian (1L maintenance) Preclinical data shows AVB-500 induces a “BRCAness” which synergizes with PARPi Phase 1b/2 Basket Trial of AVB-500 + PD1 Inhibitor Potential indications: multiple tumor types including urothelial (1L urothelial ineligible for cisplatin), and non-small-cell lung cancer (NSCLC) Above trials would complement current pipeline

Slide 36

© 2020 Aravive, Inc. | CONFIDENTIAL Market Opportunity – AVB-500: Breast, Pancreatic, NSCLC, and Bladder Indications Addressable Market Breast1 Pancreatic2 NSCLC3 Bladder4 US EU5 US EU5 US EU5 US EU5 Estimated Patient Population ~90K ~100K ~28K ~28K ~36K ~39K ~16K ~29K HER2 negative 2L+ patients (includes HR positive and TNBC) Exocrine (adenocarcinoma) – Metastatic 2L Adenocarcinoma, Squamous and Large Cell non small cell lung cancer (NSCLC) – Metastatic 2L and 3L, patients who have received platinum chemo and checkpoint inhibitor before, EGFR/ALK wt 1L advanced/metastatic, Cisplatin ineligible Numbers represent company estimates of US and EU5 (France, Germany, Italy, Spain, UK) patients with conditions covered by the Company’s targeted indications Source: Decision Resource Group, diagnosed drug-treatable patients forecast. Aravive estimates. Total Market Breast Pancreatic NSCLC* Bladder 2018 $18.1B $3.1B $14B $1.6B 2028 $45.6B $7.3B $39B $19B Annual Growth Rate 9.7% 9.1% 10.8% 28.1% Source: Decision Resource Group. Covers US, EU5 (France, Germany, Italy, Spain, UK) and Japan * Non-small-cell lung cancer

Slide 37

© 2020 Aravive, Inc. Indication Preclinical 3rd Oncology Phase 1 Phase 3 Phase 2 Phase 2a Phase 2b Anti-CTGF AVB-500 IST with AstraZeneca Phase 1b complete; plan to initiate Phase 3 trial in Q121 OVARIAN CANCER platinum resistant (PAC or PLD combination) Recruiting OVARIAN CANCER platinum resistant (PDL1i combination) Plan to initiate @ 15 mg/kg Q420 CLEAR CELL RENAL CANCER 2L+ (cabozantinib combination) Recruiting ADVANCED UROTHELIAL CANCER (PDL1 Combination) IST with EMD Serono IST= investigator sponsored trial Current Oncology Pipeline Phase 1 Phase 1b WuXi Biologics Collaboration CANCER AND FIBROSIS

Slide 38

© 2020 Aravive, Inc Objective: Identify/develop novel high-affinity bispecific antibodies against CCN2, also known as connective tissue growth factor (CTGF), implicated in cancer and fibrosis and identified from a similar target discovery screen that identified the significance of the GAS6/AXL pathway in cancer. CTGF over-expression is a hallmark of fibrosis in multiple tissues, including skin, liver, heart, lung, and kidney, and is widely thought to be required to mediate the profibrotic effects of TGFβ. Biomarker potential as levels increased in certain cancers. Overexpression associated with poor prognosis in number of cancers, including aggressive, invasive breast cancer, osteolytic breast cancer, pancreatic cancer and glioblastoma. Domain focused strategy is expected to generate a best-in-class therapeutic targeting desmoplasia and tumor growth in the clinic in 2023 This is an agent that could work as part of life cycle management with AVB-500 in certain cancers. CTGF: Collaborative Effort with WuXi Biologics

Slide 39

Summary of Program Attributes Potential Indications for Anti-CTGF Include Cancer and Fibrosis Pancreatic Cancer and CTGF Lipson et al. Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S24 Pancreatic ductal adenocarcinoma (PDAC) is the fourth most frequent cause of cancer-related deaths worldwide with a 5-year overall survival of less than 8%. Many factors contribute to the poor prognosis of PDAC, including chemoresistance and desmoplasia. CTGF appears to be a key player in PDAC progression. Blocking specific actions of CTGF could prevent or reverse PDAC desmoplasia. CTGF Domain Dependent Activities

Slide 40

© 2020 Aravive, Inc. Aravive and 3D Medicines Collaboration to Develop and Commercialize AVB-500 in Greater China Exclusive collaboration and license agreement for the development and commercialization of AVB-500 across all oncology indications in mainland China, Hong Kong, Macau, and Taiwan (Greater China) Agreement increases clinical indications and broadens geographic reach for AVB-500 Aravive to receive signing payment of $12M and be eligible to receive up to $207M in development and commercial milestone payments Potential near-term milestone payments of $6M 3D Medicines will pay Aravive tiered royalties ranging from low double digit to mid-teens as a percentage of annual net sales of AVB-500 in Greater China 3D Medicines will be responsible for all costs associated with development and commercialization activities for AVB-500 in Greater China

Slide 41

ccRCC P2 Data Flow, Assuming 2 New P1b/P2 Oncology Programs, 1 Discovery Program and 4 ISTs Development Milestones and Data Flow PROC P3 FDA feedback received Submit BLA 2H21 1H21 1H22 2H22 1H24 2H23 1H23 2H20 IST Bladder Avelumab combination (EMD Serono) PROC ccRCC P1b ccRCC IST PROC Durva combination (AZ) CTGF Discovery Program IND 1st Interim Analysis FDA mtg Phase 2 Initiation 2nd Interim Analysis

Slide 42

Data Flow, Assuming 2 New P1b/P2 Oncology Programs, 1 Discovery Program and 4 ISTs Aravive Deep Oncology Pipeline and Strategy: Following the Science HIGH UNMET NEED STRONG BIOLOGIC RATIONALE EXPAND TO OTHER CANCERS and/or BROADER PATIENT POPULATIONS HER- Breast Cancer Pancreatic NSCLC PROC Potential to combine with PARPi, bevacizumab and use 1L neoadjuvant TNBC Head and Neck Bile Duct Cancer Liver Uterine Serous Current Potential (Subject to Financing) PROC Combination with PAC, PDL1 inhibitors Clear Cell Renal Cell Carcinoma (ccRCC; 2L) Urothelial Cancer

Slide 43

Data Flow, Assuming 2 New P1b/P2 Oncology Programs, 1 Discovery Program and 4 ISTs Cash Runway EXPAND TO OTHER CANCERS and/or BROADER PATIENT POPULATIONS HER- Breast Cancer Pancreatic NSCLC PROC Potential to combine with PARPi, bevacizumab and use 1L neoadjuvant TNBC Head and Neck Bile Duct Cancer Liver Uterine Serous Current Potential (Subject to Financing) PROC Combination with PAC, PDL-1 inhibitors Clear Cell Renal Cell Cancer (ccRCC; 2L) Urothelial Cancer Cash and cash equivalent - $54M* Shares outstanding – 16.1M* Cash runway expected to fund its current operating plans into 2022** For future expansion plans, the Company will explore clinical collaborations and partnerships, and continue to be opportunistic in its financing, including non-dilutive means * As of 9/30/2020. **Includes non-dilutive cash proceeds from recently announced China licensing partnership.

Slide 44

Q4 2020 P1b/P2 ccRCC initiation at 15 mg/kg Note: Above milestones may be impacted by COVID-19 © 2020 Aravive, Inc. Q1 2021 P3 PROC initiation at 15 mg/kg Q1 2022 P3 PROC interim analysis GROWTH DRIVERS Pipeline Expansion in Oncology Global Business Development Opportunities Investigator Sponsored Trials & Anti-CTGF Discovery Program Positioned for Long-Term Growth Q3 2021 P1b ccRCC enrollment complete Q4 2021 P2 ccRCC initiation

Slide 45

© 2020 Aravive, Inc. Thank You! Halting Disease Progression in its Tracks